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Abstract
Background: Medication claims are commonly used to calculate the risk adjustment for measuring healthcare cost. 
The Rx-defined Morbidity Groups (Rx-MG) which combine the use of medication to indicate morbidity have been 
incorporated into the Adjusted Clinical Groups (ACG) Case Mix System, developed by the Johns Hopkins University. 
This study aims to verify that the Rx-MG can be used for adjusting risk and for explaining the variations in the 
healthcare cost in Taiwan.
Methods: The Longitudinal Health Insurance Database 2005 (LHID2005) was used in this study. The year 2006 was 
chosen as the baseline to predict healthcare cost (medication and total cost) in 2007. The final sample size amounted 
to 793 239 (81%) enrolees, and excluded any cases with discontinued enrolment. Two different kinds of models were 
built to predict cost: the concurrent model and the prospective model. The predictors used in the predictive models 
included age, gender, Aggregated Diagnosis Groups (ADG, diagnosis- defined morbidity groups), and Rx-defined 
Morbidity Groups. Multivariate OLS regression was used in the cost prediction modelling.
Results: The concurrent model adjusted for Rx-defined Morbidity Groups for total cost, and controlled for age and 
gender had a better predictive R-square = 0.618, compared to the model adjusted for ADGs (R2 = 0.411). The model 
combined with Rx-MGs and ADGs performed the best for concurrently predicting total cost (R2 = 0.650). For 
prospectively predicting total cost, the model combined Rx-MGs and ADGs (R2 = 0.382) performed better than the 
models adjusted by Rx-MGs (R2 = 0.360) or ADGs (R2 = 0.252) only. Similarly, the concurrent model adjusted for Rx-MGs 
predicting pharmacy cost had a better performance (R-square = 0.615), than the model adjusted for ADGs (R2 = 0.431). 
The model combined with Rx-MGs and ADGs performed the best in concurrently as well as prospectively predicting 
pharmacy cost (R2 = 0.638 and 0.505, respectively). The prospective models showed a remarkable improvement when 
adjusted by prior cost.
Conclusions: The medication-based Rx-Defined Morbidity Groups was useful in predicting pharmacy cost as well as 
total cost in Taiwan. Combining the information on medication and diagnosis as adjusters could arguably be the best 
method for explaining variations in healthcare cost.
Background
Diagnosis information is commonly used for defining
morbidities and for estimating the risk of healthcare utili-
zation. Diagnosis based comorbidity scales and risk
a d j u s t m e n t  t o o l s ,  s u c h  a s  t h e  C h a r l s o n  C o m o r b i d i t y
Index[1], Elixhauser index[2], the Johns Hopkins
Adjusted Clinical Group (ACG) case-mix system[3], and
the Diagnostic Cost Group Hierarchical Condition Cate-
gory (DCG/HCC) model[4,5] have been verified for their
effective use in adjusting healthcare costs risks [6-11].
Although administrative data seems to be comprehen-
sive, efficient, low cost, and are most likely to prevent sev-
eral common biases associated with primary data, the
accuracy and quality of the diagnosis coding remains sus-
pect [12-15]. Previous studies found that the diagnoses
identified by administrative data were highly specific but
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varied greatly in sensitivity and therefore recommended
that all available sources of data (e.g. prescription claims
database)should be included in order to overcome the
potential limitations that come with a single source of
data[15]. Pine et. al. also argued that risk-adjustment
based entirely on administrative data is imperfect
because these data do not discriminate between comor-
bidities and complications, and the limited numbers of
secondary diagnoses within the data may not properly
reflect the sickest patients [16].
Prescription claim data has several additional strengths
for capturing morbidity conditions compared to diagno-
ses data. Healthcare purchasers (insurers) that provide a
drug benefit package, claim that prescription data is often
more reliable, timely, complete, and less of a gamble than
diagnostic data [12,13,17]. In addition, for persons with a
stable, well-managed chronic disease, a medication-based
risk instrument may capture their health risk even with-
out the diagnosis information reported by the providers
[17]. Several medication-based morbidity measures have
been developed. The Chronic Disease Score (CDS) devel-
oped by a team of physicians, pharmacists, and health
services researchers at the Center for Health Studies,
Group Health Cooperative of Puget Sound (GHC), is an
early model for measuring morbidity conditions based on
prescription data [18]. Then Clark et. al. demonstrated an
approach to assign empirically derived weights for the
CDS [19]. Afterwards, the CDS was revised to incorpo-
rate more drugs used for treating diseases and conditions
in order to fulfil the needs to measure the health status
and the risk of healthcare utilization among different
types of populations [12,17,20,21]. Although these medi-
cation-based risk adjustment tools have been tested, and
were found to be valid in predicting future healthcare uti-
lization, most of these tools incorporate a coding algo-
rithm that is applied in the U.S. (i.e. required medication
data contains the U.S. National Drug Codes (NDC) or the
American Hospital Formulary Service (AHFS) Drug
codes) , which makes studies conducted outside the U.S.
operationally cumbersome.
The Johns Hopkins Adjusted Clinical Groups (ACG)
system was developed to predict healthcare utilization
and costs based on groupings of diagnoses [22-24]. The
former version of the ACG system provided the Aggre-
gated Diagnosis Codes (ADGs; 32 diagnosis clusters) and
ACGs (mutually exclusive, health status categories
defined by morbidity, age, and sex) of a given population
based on diagnosis data. Version 7.1 of the ACG system
incorporated Rx-defined Morbidity Groups (Rx-MGs)
into predictive models. Unlike earlier developed medica-
tion-based risk adjustment tools which include medica-
tion therapeutic classes to identify any limited chronic
diseases or conditions, the Rx-MG algorithm first
reduces nearly 90 000 U.S. NDCs to approx. 2700 units,
then assigns each medication use into one of the 60 Rx-
MGs based on criteria consisting of primary anatomico-
physiological system, morbidity differentiation, expected
duration, and severity [24,25]. For medication data col-
lected outside the U.S., an international mapping algo-
rithm within the ACG system also performs the Rx-MG
assignment based on the WHO Anatomical Therapeutic
Chemical (ATC) classification [26]. This feature makes
the ACG system stand out from the other medication-
based risk adjustment tools in that it can be applied to
countries where the medication data contains neither
NDC nor AHFS codes.
This study aimed to verify if the Rx-MGs of the Johns
Hopkins ACG system could be used for adjusting risk and
for explaining the variations in healthcare cost in Taiwan.
Previous researches have shown diagnosis-based ADGs
to be a valid morbidity measure as well as risk adjust
instrument for the NHI claim data in Taiwan [27,28], but
the application of Rx-MGs in empirical research remains
absent. Although in recent studies the Rx-MGs were
tested and found to be valid risk adjusters within predic-
tive models (PMs), nevertheless, those studies are based
on the limited ranking of age or populations with selected
health conditions [24,29,30]. In the present study we
c o m p a r e d  t h e  p e r f o r m a n c e  o f  R x - M G s  t o  A D G s  a n d
other diagnosis-based risk adjusters for predicting the
(concurrent and prospective) total cost and the medica-
tion cost under the NHI. The performance of Rx-MGs
models were tested with a sample that can represent the
entire population. The fit of these models was also tested
by age groups to ensure generalizability.
Methods
Risk Adjustment Instruments
Two types of risk adjusters within the Johns Hopkins
ACG system were chosen for the present study: the diag-
nosis-based ADGs and the medication-based Rx-MGs
[24]. Studies have found the Elixhauser's comorbidity
index to be statistically slightly superior to the Charlson
system at adjusting for comorbidity [31,32]. Therefore,
the Deyo's Charlson Comorbidity Index (CCI) [33] and
the Elixhauser's Index[2] were adopted as competitors to
the Rx-MGs. All of the morbidity groups or prescription
groups measured by those instruments were treated as
dichotomous variables in predictive models. We used the
ICD codes cited by Quan et. al. to determine if each of
these diagnoses were included in any of the Deyo's CCI or
Elixhauser's Index [34]. Instead of using the original cod-
ing algorithms, the enhanced ICD-9-CM coding algo-
rithms for Charlson and Elixhauser's index were adopted
to solve: (1) discrepancies among coding algorithms for
some conditions; (2) inconsistent defining of the 6 shared
comorbidities of Deyo's and Elixhauser's original ICD-9-
CM coding algorithms.Kuo and Lai BMC Health Services Research 2010, 10:126
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Study Populations
Taiwan launched a universal National Health Insurance
(NHI) Program on March 1, 1995. As of 2007, 22.60 mil-
lion of Taiwan's 22.96 million population (98.4%) were
enrolled in the NHI program [35]. And, as of December
2008, 18 829 hospitals and healthcare providers (92% of
all healthcare facilities in Taiwan) and 4180 pharmacies
were contracted by the Bureau of National Health Insur-
ance [36]. The NHI program features universal access to
healthcare, healthcare with acceptable quality, compre-
hensive benefits (inpatient and ambulatory care, dental
services, traditional Chinese medicine therapy, surgery,
examinations, laboratory tests, prescription medications,
nursing care, hospital rooms, preventive services, and
certain OTC drugs). These features make the NHI claim
data an appropriate source for comparing the perfor-
mance of diagnosis-based as well as medication-based
risk adjustment instruments.
The Longitudinal Health Insurance Database 2005
(LHID2005), which consists of one million out of 25.68
million National Health Insurance enrollees in 2005, was
used in this study. The LHID2005 database was derived
b y  t h e  B u r e a u  o f  N a t i o n a l  H e a l t h  I n s u r a n c e  ( B N H I ) ,
Department of Health and maintained by the National
Health Research Institutes (NHRI) so as to make it acces-
sible to scientists in Taiwan for research purposes. The
use of the data in this study was reviewed and granted by
the NHRI. The data used in this study has no unique
patient identifier nor any information that could violate
the privacy protection policy. All case IDs required for
data linkage were encrypted before being released. There
is no significant difference in the gender or age distribu-
tion, nor is there an average insured payroll-related
amount between the patients in the LHID2005 and the
original population [35]. This study chose 2006 as the
baseline year to predict healthcare cost (medication and
total cost) in 2007. The final sample size was 793 239
(81%) which excludes cases with discontinued enrolment
in 2006. Because those cases which were not fully
enrolled in the NHI program in 2006 had less opportu-
nity for access to healthcare covered by the NHI, the costs
of that group might be under-estimated. To test for model
fit, the sample was randomly divided into the estimation
(training) sample (476 558; 60%) and the validation (test-
ing) sample (316 681; 40%).
Data Analysis
The information on the prescriptions in LHID2005
includes outpatients/clinics, inpatients, and contracted
pharmacies (community pharmacies). Diagnosis data
combined the diagnosis codes derived from inpatient and
outpatient/clinic claims. Studies show that the truncation
of healthcare expenditures in predictive models provides
more stable and more robust estimates than using raw
dollars [24,37]. But, the cut-offs used for defining the out-
liers in those researches ranged in general from 0.5% to
20% [38-43], or were set for a fixed amount by the
researchers [17,24]. In the present study, we capped phar-
macy cost and the total cost at the top 1% of the cases,
which are the maximums of USD 1846 and USD 7538 in
2006 as well as USD 2062 and USD 9446 in 2007, respec-
tively.
The diagnoses derived from the National Health Insur-
ance claim data were entered into the Johns Hopkins
ACG system for ADGs assignment. The prescription
codes within the claim data were first mapped to the
WHO ATC codes, then entered into the Johns Hopkins
ACG system for Rx-MGs assignment. For measuring the
Charlson Index and the Elixhauser's index, the diagnoses
for all cases were first screened by a pre-defined algo-
rithm to improve the specificity of these codes, excluding
outpatient diagnoses which were identified as with a
same disease/condition but had been reported less than 3
times within the year, or it they all appeared in the same
month. The exclusion criteria was not applied for the data
which were input in the ACG system because the precise
algorithm for assigning each single ICD code to the ADG
was not disclosed by the Johns Hopkins ACG team.
Another concern was that the ADG categories include
acute diseases/conditions that are not included by the
Charlson Index and the Elixhauser's index. Therefore,
excluding those ICD codes that were reported less than 3
times may underestimate the existing acute diseases/con-
ditions.
Multivariate OLS regression was used in the cost pre-
diction modelling. The risk adjusters used in the predic-
tive models included age, gender, Deyo's CCI,
Elixhauser's Index, ADGs, and Rx-MGs. Because previ-
ous studies found that prior cost is a comparatively accu-
rate predictor of true costs [44], it was also included for
prospective prediction in this study. Because the relation-
ship between prior- and current-year costs may not be
strictly linear [45], we also examined a functional form
that included a squared term of costs in 2006. There were
five alternative models for the concurrent prediction and
seven models for the prospective prediction fitted in this
study. For concurrent prediction, the first model con-
trolled for age and gender only, and was followed by mod-
els including Deyo's CCI, Elixhauser's index, ADGs, and
Rx-MGs. The fifth model combined both ADGs and Rx-
MGs for comparing models that included only one of
these indexes. For prospective prediction, the alternative
models included the five for concurrent prediction, as
well as added models that were adjusted by prior cost and
the square term of prior cost. The coefficients of each
morbidity group within the selected indices were esti-
mated from the estimation sample. Then the coefficients,
excluding those which were statistically non-significantKuo and Lai BMC Health Services Research 2010, 10:126
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in each alternative model (see appendix), were applied in
the validation sample. The performance of each alterna-
tive model was compared by its predictive R-square and
mean of absolute prediction error (MAPE) estimated by
the validation sample. Another indicator was also pro-
vided in which the MAPE is divided by the mean of cost,
so that the MAPEs could be compared across the models
with different means of cost. The fit of the selected mod-
els was also tested by age groups (< 18, 18-64, > = 65) for
sensitivity analysis. The pharmacy cost and total cost of
each group were capped at the top 1% of the cases.
Results
Patient characteristics
As shown in Table 1, the estimation and the validation
sample have the same distribution of age, gender, number
of Rx-MGs, and healthcare utilizations. There were 11%
of cases with zero Rx-MGs in the estimation samples as
well as in the validation sample. The average numbers of
Rx-MGs for both samples are 7.19 and 7.20. Also, 29% of
cases were with more than 10 Rx-MGs. Compared to the
year 2006, the mean of the total cost increased by 12%
and the mean of the total cost increased by about 10% in
2007.
The distribution of each Rx-MG was similar in both
samples (see Table 2). A few Rx-MGs had cases less than
1%, and the number of cases for 'Immune disorders'
(ALLx040) and 'Cystic fibrosis' (RESx030) were less than
100. Prevalence of several acute diseases/conditions,
identified by Rx-MGs, was above 50% among the two
samples: 'Allergy/immunology, acute minor', 'Gastroin-
testinal/hepatic, acute minor', 'Pain and inflammation',
'Infectious, acute minor', and 'Respiratory, acute minor'.
The prevalence of all Rx-MGs had no significant differ-
ences among the two samples, except for 'Endocrine,
Bone disorders'
Performance comparisons among predictive models
The predictive R-squares of five models predicting total
cost concurrently ranged from 0.089 to 0.650 (see Table
Table 1: Characteristics of estimation and validation samples
Estimation (n = 476 558) 60% Validation (n = 316 681) 40% p-value
Characteristics (n) (%) (n) (%)
Age 0.641
0-17 105 430 22.1% 70 449 22.2%
18-44 193 270 40.6% 128 267 40.5%
45-64 125 831 26.4% 83 385 26.3%
> = 65 52 027 10.9% 34 580 10.9%
Mean age (S. D.) 37.3 (21.0) 37.3 (21.0)
Gender 0.284
Female 241 477 50.7% 160 854 50.8%
Rx_MGs 0.368
0 53 395 11.2% 35 099 11.1%
< = 3 63 060 13.2% 41 706 13.2%
< = 6 108 881 22.8% 72 648 22.9%
< = 9 113 026 23.7% 75 358 23.8%
> = 10 138 196 29.0% 91 870 29.0%
Mean number of Rx_MGs (S. D.) 7.19 (4.98) 7.20 (4.97) 0.247
Mean of total cost (USDa) (S. D.)
Y2006 598 (2063.4) 600 (2410.4) 0.626
Y2007 668 (2339.7) 672 (2934.7) 0.575
Mean of pharmacy cost (USD a) (S. D.)
Y2006 155 (752.2) 158 (1497.9) 0.298
Y2007 169 (808.5) 174 (1916.1) 0.172
a. USD 1. = NTD 32.5Kuo and Lai BMC Health Services Research 2010, 10:126
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Table 2: Frequency of Rx-MGs in 2006, by study sample
Estimation
(n = 476 558)
60%
Validation
(n = 316 681)
40%
p-value
Rx-MG label Description (n)a (%) (n) a (%)
Allergy/immunology
ALLx010 Acute minor 252 733 53.00% 168 474 53.20% 0.145
ALLx030 Chronic inflammatory 86 509 18.20% 57 687 18.20% 0.474
ALLx040 Immune disorders 28 < 0.1% 18 < 0.1% 0.913
ALLx050 Transplant 437 0.10% 277 0.10% 0.538
Cardiovascular
CARx010 Chronic medical 17 517 3.70% 11 817 3.70% 0.197
CARx020 Congestive heart failure 14 754 3.10% 9 956 3.10% 0.229
CARx030 High blood pressure 79 187 16.60% 52 759 16.70% 0.610
CARx040 Hyperlipidemia 21 877 4.60% 14 572 4.60% 0.821
CARx050 Vascular disorders 57 775 12.10% 38 503 12.20% 0.641
Ears-nose-throat
EARx010 Acute minor 3 653 0.80% 2 424 0.80% 0.956
Endocrine
ENDx010 Bone disorders 2 088 0.40% 1 492 0.50% 0.032
ENDx020 Chronic medical 17 059 3.60% 11 413 3.60% 0.569
ENDx030 Diabetes with insulin 4 813 1.00% 3 167 1.00% 0.666
ENDx040 Diabetes without insulin 21 991 4.60% 14 634 4.60% 0.892
ENDx050 Thyroid disorders 4 050 0.80% 2 681 0.80% 0.877
Eye
EYEx010 Acute minor: curative 103 889 21.80% 69 173 21.80% 0.648
EYEx020 Acute minor: palliative 79 750 16.70% 52 753 16.70% 0.371
EYEx030 Glaucoma 31 213 6.50% 20 959 6.60% 0.227
Female reproductive
FREx010 Hormone regulation 16 101 3.40% 10 643 3.40% 0.667
FREx020 Infertility 2 772 0.60% 1 826 0.60% 0.771
FREx030 Pregnancy and delivery 10 894 2.30% 7 113 2.20% 0.243
Gastrointestinal/hepatic
GASx010 Acute minor 288 597 60.60% 191 999 60.60% 0.533
GASx020 Chronic liver disease 11 622 2.40% 7 708 2.40% 0.893
GASx030 Chronic stable 140 349 29.50% 93 089 29.40% 0.596
GASx040 Inflammatory bowel disease 918 0.20% 613 0.20% 0.926
GASx050 Pancreatic disorder 33 833 7.10% 22 647 7.20% 0.379
GASx060 Peptic disease 91 510 19.20% 61 344 19.40% 0.062
General signs and symptoms
GSIx010 Nausea and vomiting 69 209 14.50% 46 281 14.60% 0.257
GSIx020 Pain 108 551 22.80% 72 225 22.80% 0.765
GSIx030 Pain and inflammation 371 310 77.90% 247 044 78.00% 0.316Kuo and Lai BMC Health Services Research 2010, 10:126
http://www.biomedcentral.com/1472-6963/10/126
Page 6 of 12
Genitourinary
GURx010 Acute minor 27 817 5.80% 18 636 5.90% 0.375
GURx020 Chronic renal failure 1 086 0.20% 666 0.20% 0.102
Hematologic
HEMx010 Coagulation disorders 35 047 7.40% 23 460 7.40% 0.369
Infections
INFx010 Acute major 26 329 5.50% 17 191 5.40% 0.065
INFx020 Acute minor 250 114 52.50% 165 757 52.30% 0.217
INFx030 HIV/AIDS 308 0.10% 203 0.10% 0.928
INFx040 Tuberculosis 1 350 0.30% 883 0.30% 0.714
Malignancies
MALx010 Malignancies 3 176 0.70% 2 074 0.70% 0.535
Musculoskeletal
MUSx010 Gout 17 046 3.60% 11 181 3.50% 0.277
MUSx020 Inflammatory conditions 515 0.10% 342 0.10% 0.992
Neurologic
NURx010 Alzheimer's disease 194 < 0.1% 147 < 0.1% 0.230
NURx020 Chronic medical 56 048 11.80% 37 471 11.80% 0.334
NURx030 Migraine headache 5 341 1.10% 3 588 1.10% 0.612
NURx040 Parkinson's disease 11 633 2.40% 7 656 2.40% 0.506
NURx050 Seizure disorder 8 760 1.80% 5 846 1.80% 0.799
Psychosocial
PSYx010 Attention-deficit disorder 692 0.10% 465 0.10% 0.852
PSYx020 Addiction 2 531 0.50% 1 614 0.50% 0.195
PSYx030 Anxiety 91 748 19.30% 61 452 19.40% 0.091
PSYx040 Depression 19 482 4.10% 12 951 4.10% 0.973
PSYx050 Acute minor 32 618 6.80% 21 680 6.80% 0.979
PSYx060 Chronic unstable 29 899 6.30% 20 190 6.40% 0.069
Respiratory
RESx010 Acute minor 301 188 63.20% 200 630 63.40% 0.166
RESx020 Chronic medical 29 992 6.30% 19 890 6.30% 0.820
RESx030 Cystic fibrosis 77 < 0.1% 47 < 0.1% 0.646
RESx040 Airway hyper-reactivity 164 532 34.50% 109 696 34.60% 0.295
Skin
SKNx010 Acne 23 862 5.00% 15 892 5.00% 0.824
SKNx020 Acute and recurrent 179 162 37.60% 119 167 37.60% 0.753
SKNx030 Chronic medical 3 276 0.70% 2 100 0.70% 0.196
Toxic effects/adverse effects
TOXx010 Acute major 574 0.10% 381 0.10% 0.986
ZZZx000 Other and nonspecific 
medications
157 388 33.00% 104 784 33.10% 0.564
a Represents the number of cases which has the selected prescriptions contributed to the Rx-MG (multiple counting, since cases are not 
mutually exclusive in each Rx-MG).
Table 2: Frequency of Rx-MGs in 2006, by study sample (Continued)Kuo and Lai BMC Health Services Research 2010, 10:126
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3). For those models with cost adjusted by diagnosis-
based morbidity measures, the ADGs model performed
better than others. The Rx-MGs model has a predictive
R-square 0.618, which explains the 21% more variance
than the ADGs model. The model that combined ADGs
and Rx-MGs had the highest predictive R-square (0.650)
as well as the lowest MAPE rate (54.6%) among all mod-
els. The prospective prediction models had lower predic-
tive R-squares than the concurrent prediction models. All
of the seven models explained less than 50% of the varia-
tions in the total cost for 2007. Similar to the concurrent
prediction models, the prospective prediction model
which combined ADGs and Rx-MGs had a predictive R-
square (0.382) that was higher than those using either
ADGs or Rx-MGs. The MAPE rate was the lowest
(75.9%) among all models except for those that included
prior cost. The model which included prior cost
increased 0.08 in R-square. The model with the square
term for prior cost had no considerable improvement in
predictive R-square.
A s  s h o w n  i n  T a b l e  4 ,  t h e  R x - M G s  m o d e l s  a l s o  p e r -
formed better than the diagnosis-based models for pre-
dicting medication cost concurrently and prospectively.
But, unlike the results of the total cost prediction models,
the ADGs models had a lower predictive R-squares and a
h i g h e r  M A P E  r a t e  t h a n  t h e  m o d e l  a d j u s t e d  b y  E l i x -
hauser's index for predicting medication cost. The mod-
els which combined ADGs and Rx-MGs also improved
slightly over the model adjusted by Rx-MGs only. The
ADGs and Rx-MGs combined model had a remarkable
improvement in predictive R-square after adding the pre-
dictor of prior medication cost. The predictive R-square
seemed to have only a negligible improvement if the
square term of prior medication cost was added.
Comparing model performance across age groups
The performance of three alternative models was com-
pared across three age groups: < 18, 18-64, > = 65. After
being capped at the 99-percentile of costs for all age
groups, the result showed that models that applied to all
age ranks had the highest predictive R-squares of all other
sub-samples (see Table 5). The 18-64 year old age group
had the highest predictive R-squares for all alternative
models compared to the other two age groups. For all
three sub-samples, the performance of the predictive
models was similar to the whole sample: the models that
were adjusted for prior cost performed the best. The
result showed that R-squares for the 'under 18' age group
were the lowest among all three sub-samples, implying
that the predictive models are not well explained varia-
tions of costs within the sample.
Discussion
This study has demonstrated that the Rx-Defined Mor-
bidity Groups are applicable for predicting the total cost
and the medication cost in a universal health insurance
system. Although a few articles attempted to predict or
explain variations of medication use by applying the
Johns Hopkins ACG case-mix system, these analytical
models are mainly based on diagnosis-based risk adjust-
ers (i.e. the EDCs, ADGs, or ACGs) within the ACG sys-
tem [10,11,46]. Two recent articles reported studies that
had applied the Johns Hopkins ACG system for identify-
ing high-risk patients and predicting healthcare utiliza-
tion. However, the authors chose predictive models
embedded within the ACG system (i.e. the Dx-PM, Rx-
PM, and DxRx-PM) instead of adjusting risks by original
morbidity groups (i.e. the ADGs or Rx-MGs) [24,47].
Therefore, we believe that the present article is the first
one to describe an empirical study using Rx-MGs for
healthcare cost prediction as well as comparing the
model performance with other diagnosis-based predic-
tive models.
In this study, the model adjusted by Rx-MGs could
explain over 60% of the variations for total cost and medi-
cation cost in the concurrent year. Clark et. al. used two
versions of the Chronic Disease Score to explain varia-
tions of total cost, the R-squares for concurrent predic-
tion were 0.09 and 0.19 [19]. Fishman et. al. used the Rx-
Risk model to predict healthcare cost, and the validation
R-square of that model was 0.0874. They also took sensi-
tivity analyses for cases with patients younger than 18 or
older than 18. The R-squares for these two sub-samples
were 0.083 and 0.077, respectively [17]. Sales et. al. used
Rx-Risk-V, a modification from Rx-Risk for the veteran
population, to predict cost. The R-square of the concur-
rent prediction was 0.202 [48]. Compared to former
researches using medication-based morbidity measures
to predict cost, the performance of the Rx-MGs model is
relatively better than others. This study also found that
the Rx-MGs model is applicable to all the different age
groups, although the performance varied among these
groups. The Rx-MGs model also performed better than
other diagnosis-based alternative models in this study.
This finding is consistent with other studies which found
that prescription data are superior for predicting phar-
macy cost [6,24]. However, our study also found that the
Rx-MGs model is superior for predicting total cost. One
possible explanation for the superior performance of the
Rx-MGs model compared to other medication based
morbidity measures reported by previous studies is that
the NHI pays for almost all prescription drugs, except for
those that are very new in the market, expensive, and not
yet approved by the Department of Health. Furthermore,
this study aggregated prescriptions from outpatients/
clinics, inpatients, and community pharmacies. This
comprehensive data was intended to help capture all pre-
scription-related morbidities for each case, something
that was not done in similar studies. In addition, the Rx-Kuo and Lai BMC Health Services Research 2010, 10:126
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MGs consisted of not only the chronic diseases or condi-
tions, but they also included several acute diseases or
syndromes. This feature makes the Rx-MGs stand out
from other chronic disease focused instruments (e.g. the
Chronic Disease Score) by capturing all possible risks for
healthcare utilization. In addition, although the ADGs do
capture the diagnoses of acute diseases or syndromes, the
number of ADG categories is smaller than that of the Rx-
MGs, which might explain why the performance of Rx-
MGs models are superior to the ADGs models. Another
possible explanation is that the annual medication cost is
merely one fourth of the annual total healthcare cost in
NHI. Therefore the model that can explain more varia-
tions of medication cost is expected to have a better per-
formance for predicting total cost. However, the real
cause for the gap in performance between ADGs and Rx-
MGs models needs further investigation.
The predictive R-squares of the ADGs models in this
study are larger than those reported by two other similar
studies which also used Taiwan NHI data [27,38]. These
two earlier studies did not enforce the 'full enrolment' cri-
teria as applied in our study. Therefore the disease bur-
den of those cases selected in these two earlier studies
may not be equally accessed. Second, we capped the cost
at the 99-percentile, which might be the most critical
point to explain the improvement in model performance.
We conducted another analysis using original cost (with-
out capping the cost) for the prediction models. The
result of that analysis showed that age/sex also adjusted
for 4% to 5% of the variances, which is quite similar to Lee
and Huang's findings[28]. Chang and Weiner also found
that after truncating the cost at top 0.5%, the perfor-
mance of the models improved significantly[38]. After
adjusting for prior healthcare utilization, our proposed
model combined with Rx-MGs and ADGs out-performed
others models for predicting future medication cost,
which could explain over 68% of the variations for future
medication cost. The findings of this study are similar to
the findings of Forrest, et al.'s study which showed that
the Combined Diagnostic/Medication Predictive Models
(DxRx-PMs) had the highest R-squares for explaining
variations of pharmacy charges and total healthcare
charges [24]. Other studies have shown that adding diag-
nosis-based morbidity measures to medication-based
models could improve the prediction of total healthcare
utilization [6,19,49,50]. However, those findings sup-
ported combining those two types of measure to improve
cost prediction. On the other hand, Schneeweiss et.al.
compared the performance of four diagnosis-based and
two medication-based comorbidity scores to predict
mortality. They found that while diagnoses-based scores
performed better than medication-based scores in pre-
dicting future mortality, combining diagnoses and medi-
cation-based scores showed an improvement in
predicting mortality [49]. The strength of employing all
available diagnosis and prescription data is that some
potential risk factors may not be captured in a single
morbidity measurement, and each morbidity measure-
ment captures different risks. Therefore, combining dif-
ferent morbidity measures in a given predictive model
Table 3: Predictive models for total cost
Morbidity 
Index
Source of 
morbidity
Predictors Model performance - prediction of total cost
Concurrent (year 2006) Prospective (year 2007)
R2 MAPE MAPE*(%) R2 MAPE MAPE*(%)
(none) Age + gender 0.089 505.9 99.5 0.092 582.9 102.9
Deyo's CCI Diagnosis Age + gender + CCIs 0.345 409.0 80.5 0.273 496.4 87.6
Elixhauser's 
Index
Diagnosis Age + gender + E. Index 0.373 390.8 76.9 0.294 480.3 84.8
ADG Diagnosis Age + gender + ADGs 0.411 360.0 70.8 0.252 486.1 85.8
Rx-MG Medication Age + gender + Rx-MGs 0.618 297.5 58.5 0.360 448.5 79.1
ADG + Rx-MG Diagnosis & 
medication
Age + gender + ADGs + 
Rx-MGs
0.650 277.4 54.6 0.382 430.4 75.9
ADG + Rx-MG Diagnosis & 
medication
Age + gender + ADGs + 
Rx-MGs + prior total cost
0.465 386.1 68.1
ADG + Rx-MG Diagnosis & 
medication
Age + gender + ADGs + 
Rx-MGs + prior total cost 
+ (prior total cost)2
0.465 389.2 68.7
MAPE, mean absolute prediction error; MAPE*, MAPE divided by the mean of costKuo and Lai BMC Health Services Research 2010, 10:126
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can be more informative than employing just one.
Although using more than one morbidity measurement
in a single model may raise the concern of multicollinear-
ity , an empirical study showed that there is only a low
correlation between different measures [51].
Previous studies have shown that combined prior costs
and morbidity measures are important in determining
future high cost patients [24,30,41]. Hsu et. al. found that
incorporating information of the previous year's drug use
or cost into the risk adjustment approach would greatly
improve the accuracy of the prediction. They pointed out
that drug costs tend to be stable from year to year and are
more predictable than other types of medical costs.
Therefore, ignoring past costs may result in preventable
misallocation of resources and creates a strong incentives
for reverse patient selection [45]. The data of our study
also support that predictive models combined with Rx-
MGs, ADGs, and prior cost performed the best in pre-
dicting future cost. However, investigators have argued
that this could provide incentives to increase utilization
or to favor a specific style of practicing medicine in addi-
tion to medical needs. Thus, payment models that
include utilization measures among the predictor vari-
ables must proceed with caution [41,52].
Compared to other diagnosis-based predictive models,
this study has demonstrated that the Rx-MGs model out-
performs all other diagnosis-based models in explaining
or predicting healthcare utilization. In future applica-
tions, the Rx-MGs could be applied for describing and
comparing disease patterns among populations. The
models which use Rx-MGs alone or combined with
ADGs could also be applied for helping local health
authorities or case managers to identify high risk popula-
tions for disease management programs [24,29,53]. A
comprehensive and integrated care delivery system could
be provided to those who have a high utilization of
healthcare but have a low severity of illness, instead of
delivering fragmented acute care to them. The Rx-MGs
or other predictive models within the ACG system could
also be tested for their efficiency and appropriateness in
allocating healthcare resources or setting payment rates
by future researchers or policy makers.
There are several limitations to this study. First, we
used ADGs and Rx-MGs as risk adjusters for comparing
them with two other commonly used morbidity mea-
sures. However, the Johns Hopkins ACG system provides
prediction models (PMs) which include disease or frailty
markers other than ADGs or Rx-MGs, and they have a
better performance than the ADGs or other diagnosis-
based measures. The PMs were not included as compet-
ing models in this study because the 'risk scores' provided
by the Dx-PM or Rx-PM as the summary measures of dis-
ease burden were provided by the ACG system [24].
Although the more efficient risk adjusters included in the
prediction models could be expected to provide the bet-
ter performance in predicting cost, the performance of
Table 4: Predictive models for medication cost
Morbidity 
Index
Source of 
morbidity
Predictors Model performance - prediction of medication cost
Concurrent (year 2006) Prospective (year 2007)
R2 MAPE MAPE* (%) R2 MAPE MAPE* (%)
(none) Age + gender 0.151 155.2 118.9 0.153 166.0 119.1
Deyo's CCI Diagnosis Age + gender + CCIs 0.426 113.5 87.0 0.366 129.6 93.0
Elixhauser's 
Index
Diagnosis Age + gender + E. Index 0.514 97.4 74.7 0.434 115.5 82.9
ADG Diagnosis Age + gender + ADGs 0.431 114.4 87.7 0.360 131.2 94.2
Rx-MG Medication Age + gender + Rx-MGs 0.615 89.6 68.6 0.485 110.3 79.1
ADG + Rx-MG Diagnosis & 
medication
Age + gender + ADGs + 
Rx-MGs
0.638 85.6 65.6 0.505 106.2 76.2
ADG + Rx-MG Diagnosis & 
medication
Age + gender + ADGs + 
Rx-MGs + prior 
medication cost
0.684 73.8 53.0
ADG + Rx-MG Diagnosis & 
medication
Age + gender + ADGs + 
Rx-MGs + prior 
medication cost + (prior 
medication cost)2
0.684 73.7 52.9
MAPE, mean absolute prediction error; MAPE*, MAPE divided by the mean of costKuo and Lai BMC Health Services Research 2010, 10:126
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Table 5: Total cost predictive models for specific age groups
Predictors Variation explained by model (R2)
Total cost Medication cost
(all) Age < 18 Age 18-64 Age > = 65 (all) Age < 18 Age 18-64 Age > = 65
Concurrent prediction (year 2006)
Age + gender + Rx-MGs 0.618 0.471 0.589 0.552 0.615 0.399 0.571 0.528
Age + gender + ADGs + Rx-MGs 0.650 0.602 0.629 0.570 0.638 0.520 0.600 0.543
Prospective prediction (year 2007)
Age + gender + Rx-MGs 0.360 0.220 0.333 0.268 0.485 0.244 0.446 0.287
Age + gender + ADGs + Rx-MGs 0.382 0.281 0.359 0.278 0.505 0.308 0.472 0.300
Age + gender + ADGs + Rx-MGs 
+ prior cost
0.465 0.359 0.451 0.376 0.684 0.477 0.677 0.442
those models is somehow hard to compare with other
models that are wholly based on morbidity measures (e.g.
the Charlson Comorbidity Index). Second, we excluded
those cases with discontinued enrolment in 2006 to
ensure equality accessibility for healthcare covered by
NHI. However, the reasons for the discontinued enrol-
ment in NHI might be very diverse. Thus these cases that
were excluded by our study might be high-risk users (e.g.
cancer patients at the end-of-life year) or healthy users
(e.g. young students studying abroad). Hence the analyti-
cal strategy used in this study could limit its generalizabil-
ity. Another limitation is the approach to treat outliers in
this study. Although we capped at the top 1% of costs,
those cases with capped costs generally accounted for
approximately 25% of the healthcare expenditure. That
implies that the predictive models applied to real data
cannot perform as well as in this study. Another analysis
also found that when applying the predictive models to
those high-risk users with actual cost data, the perfor-
mance of the models declines significantly. This finding
seems to suggest that in order to address this issue it
might be best to identify and manage those cases by using
the risk adjustment instruments, instead of "predicting"
their future healthcare utilization [24,29]. The fourth
potential limitation in this study is that we failed to incor-
porate socio-economic status indicators into the predic-
tive models. However, in a recent article the authors
argued that adding socioeconomic patient characteristics
improves the predictive model only slightly [54]. The
information on socio-economic status is quite limited in
the NHI database. We carried out another analysis to
incorporate household income into the predictive mod-
els. The results showed that as a proxy of the socio-eco-
nomic status it did not have a statistically significant
impact on costs.
Conclusions
This study demonstrated that compared to other diagno-
sis-based predictive models, the Rx-MGs model out-per-
forms all other models in explaining variations of cost
and predicting future healthcare utilization. For countries
or regions that routinely collect prescription claim data,
the Rx-MGs within the Johns Hopkins ACG case-mix
system could be applied to predict future healthcare utili-
zation as well as allocate resources for healthcare.
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